Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

469 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators. Pfisterer J, et al. Among authors: mahner s. Lancet Oncol. 2020 May;21(5):699-709. doi: 10.1016/S1470-2045(20)30142-X. Epub 2020 Apr 16. Lancet Oncol. 2020. PMID: 32305099 Clinical Trial.
Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J, Camara O, Schmidt M, Mahner S, Seipelt G, Otremba B, Schmalfeldt B, Tesch H, Lorenz-Schlüter C, Oskay-Ozcelik G; North-Eastern German Society of Gynecological Oncology. Sehouli J, et al. Among authors: mahner s. Cancer Chemother Pharmacol. 2009 Aug;64(3):585-91. doi: 10.1007/s00280-008-0909-1. Epub 2009 Jan 21. Cancer Chemother Pharmacol. 2009. PMID: 19156414
Role of cytoreductive surgery in recurrent ovarian cancer.
Harter P, Hilpert F, Mahner S, Kommoss S, Heitz F, du Bois A. Harter P, et al. Among authors: mahner s. Expert Rev Anticancer Ther. 2009 Jul;9(7):917-22. doi: 10.1586/era.09.49. Expert Rev Anticancer Ther. 2009. PMID: 19589031 Review.
Serum carbonic anhydrase IX during first-line therapy of ovarian cancer.
Woelber L, Mueller V, Eulenburg C, Schwarz J, Carney W, Jaenicke F, Milde-Langosch K, Mahner S. Woelber L, et al. Among authors: mahner s. Gynecol Oncol. 2010 May;117(2):183-8. doi: 10.1016/j.ygyno.2009.11.029. Epub 2010 Jan 6. Gynecol Oncol. 2010. PMID: 20051287
A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer.
Sehouli J, Camara O, Mahner S, Bauknecht T, Lichtenegger W, Runnebaum I, Look K, Jaenicke F, Oskay-Oezcelik G. Sehouli J, et al. Among authors: mahner s. Cancer Chemother Pharmacol. 2010 Oct;66(5):861-8. doi: 10.1007/s00280-009-1230-3. Epub 2010 Jan 7. Cancer Chemother Pharmacol. 2010. PMID: 20054549 Clinical Trial.
Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study.
Sehouli J, Pietzner K, Harter P, Münstedt K, Mahner S, Hasenburg A, Camara O, Wimberger P, Boehmer D, Buehling KJ, Richter R, El Khalfaoui K, Oskay-Ozcelik G. Sehouli J, et al. Among authors: mahner s. Ann Oncol. 2010 Nov;21(11):2201-2205. doi: 10.1093/annonc/mdq229. Epub 2010 May 3. Ann Oncol. 2010. PMID: 20439341 Free article.
469 results